CA2073281A1 - Isatineoxime derivatives, their preparation and use - Google Patents
Isatineoxime derivatives, their preparation and useInfo
- Publication number
- CA2073281A1 CA2073281A1 CA002073281A CA2073281A CA2073281A1 CA 2073281 A1 CA2073281 A1 CA 2073281A1 CA 002073281 A CA002073281 A CA 002073281A CA 2073281 A CA2073281 A CA 2073281A CA 2073281 A1 CA2073281 A1 CA 2073281A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cyclic
- branched
- alkyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 title description 4
- NGXLTYPELAIUHE-UHFFFAOYSA-N 2-(hydroxyamino)indol-3-one Chemical class C1=CC=C2C(=O)C(NO)=NC2=C1 NGXLTYPELAIUHE-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 11
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108010011562 aspartic acid receptor Proteins 0.000 claims abstract description 6
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical class C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000002461 excitatory amino acid Effects 0.000 description 9
- 239000003257 excitatory amino acid Substances 0.000 description 9
- CSHJCESYHRWFCE-UHFFFAOYSA-N 2-amino-3-hydroxy-2-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1C(N)(CO)C(O)=O CSHJCESYHRWFCE-UHFFFAOYSA-N 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 206010053398 Clonic convulsion Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VRZHPQRMHBSHLW-UHFFFAOYSA-N 3-hydroxyimino-3a,4,5,9b-tetrahydro-1H-benzo[g]indol-2-one Chemical compound N1C(C(C2CCC3=C(C12)C=CC=C3)=NO)=O VRZHPQRMHBSHLW-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000001393 Lathyrism Diseases 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
- Lubricants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72747991A | 1991-07-09 | 1991-07-09 | |
| US07/727,479 | 1991-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2073281A1 true CA2073281A1 (en) | 1993-01-10 |
Family
ID=24922831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002073281A Abandoned CA2073281A1 (en) | 1991-07-09 | 1992-07-07 | Isatineoxime derivatives, their preparation and use |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0522494B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP3270524B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE143659T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU655643B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2073281A1 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69214205T2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK0522494T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2094850T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI102276B (cg-RX-API-DMAC10.html) |
| GR (1) | GR3021814T3 (cg-RX-API-DMAC10.html) |
| IE (1) | IE921730A1 (cg-RX-API-DMAC10.html) |
| NO (1) | NO178620C (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA924118B (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK81593D0 (da) * | 1993-07-07 | 1993-07-07 | Neurosearch As | Nye isatinoximderivater, deres fremstilling og anvendelse |
| AR016384A1 (es) * | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
| WO2000071102A2 (en) * | 1999-05-19 | 2000-11-30 | Neurosearch A/S | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE69677B1 (en) * | 1989-12-11 | 1996-10-02 | Neurosearch As | Isatine derivatives their preparation and use |
| US5164404A (en) * | 1991-03-15 | 1992-11-17 | Neurosearch A/S | Hydrazone derivatives and their use |
-
1992
- 1992-05-29 AU AU17268/92A patent/AU655643B2/en not_active Ceased
- 1992-06-05 ZA ZA924118A patent/ZA924118B/xx unknown
- 1992-06-30 FI FI923032A patent/FI102276B/fi active
- 1992-07-01 IE IE173092A patent/IE921730A1/en not_active Application Discontinuation
- 1992-07-07 AT AT92111478T patent/ATE143659T1/de not_active IP Right Cessation
- 1992-07-07 ES ES92111478T patent/ES2094850T3/es not_active Expired - Lifetime
- 1992-07-07 DE DE69214205T patent/DE69214205T2/de not_active Expired - Lifetime
- 1992-07-07 CA CA002073281A patent/CA2073281A1/en not_active Abandoned
- 1992-07-07 DK DK92111478.1T patent/DK0522494T3/da active
- 1992-07-07 JP JP17991692A patent/JP3270524B2/ja not_active Expired - Fee Related
- 1992-07-07 EP EP92111478A patent/EP0522494B1/en not_active Expired - Lifetime
- 1992-07-08 NO NO922686A patent/NO178620C/no unknown
-
1996
- 1996-11-28 GR GR960403205T patent/GR3021814T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO178620C (no) | 1996-05-02 |
| ATE143659T1 (de) | 1996-10-15 |
| DK0522494T3 (cg-RX-API-DMAC10.html) | 1997-03-03 |
| FI102276B1 (fi) | 1998-11-13 |
| FI923032L (fi) | 1993-01-10 |
| JP3270524B2 (ja) | 2002-04-02 |
| EP0522494A1 (en) | 1993-01-13 |
| NO922686D0 (no) | 1992-07-08 |
| DE69214205D1 (de) | 1996-11-07 |
| IE921730A1 (en) | 1993-01-13 |
| AU1726892A (en) | 1993-01-14 |
| NO922686L (no) | 1993-01-11 |
| EP0522494B1 (en) | 1996-10-02 |
| GR3021814T3 (en) | 1997-02-28 |
| FI923032A0 (fi) | 1992-06-30 |
| ES2094850T3 (es) | 1997-02-01 |
| DE69214205T2 (de) | 1997-02-06 |
| ZA924118B (en) | 1993-08-03 |
| JPH05201976A (ja) | 1993-08-10 |
| AU655643B2 (en) | 1995-01-05 |
| FI102276B (fi) | 1998-11-13 |
| NO178620B (no) | 1996-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007102531A1 (ja) | 併用薬 | |
| JPH06504054A (ja) | 特定アミノメチルフェニルイミダゾール誘導体、新種のドーパミン受容体サブタイプの特定リガンド | |
| RU2190612C2 (ru) | Новые производные индол-2,3-дион-3-оксима | |
| EP1036794A1 (en) | 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof | |
| WO2008097538A1 (en) | Therapeutic agents | |
| CN1803806A (zh) | 抗肿瘤联合药物 | |
| WO2016155545A1 (zh) | 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| JPH0228181A (ja) | チエノジアゼピン化合物 | |
| WO2007049771A1 (ja) | 塩基性基を含有する化合物およびその用途 | |
| PT3013814T (pt) | Compostos de tetrahidrocarbazol e carbazol carboxamida substituídos úteis como inibidores de quinases | |
| KR101133959B1 (ko) | 면역조절 헤테로고리 화합물 | |
| MXPA06014471A (es) | Derivados de pirrolopiridina. | |
| CA2076948C (en) | Isatineoxime derivatives, their preparation and use | |
| CA2119579A1 (en) | Heterocyclic compounds and their preparation and use | |
| JP2011201777A (ja) | 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体 | |
| CN1167698C (zh) | 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物 | |
| WO2010010934A1 (ja) | ｐ－置換アリールアセトアミドを有するヘテロシクリデン誘導体 | |
| JPH09506354A (ja) | 免疫調節剤としての置換ピロロアントラセン類及びピロロアントラセンジオン類 | |
| US6239128B1 (en) | Indole-2,3-dione-3-oxime derivatives for therapeutic use | |
| JPH09506355A (ja) | 免疫−調節剤としてのアントラセンスピロ−ピロリジン類 | |
| US7595336B2 (en) | Isatine derivatives with neurotrophic activity | |
| EP0522494B1 (en) | Novel isatineoxime derivatives, their preparation and use | |
| US5223527A (en) | Isatineoxime derivatives and their use | |
| CZ321095A3 (en) | Heterocyclic compounds | |
| JP2011201776A (ja) | ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |